Lacktman Quoted on Telehealth’s Expansion to Complex Medical Cases
March 18, 2017
Modern Healthcare
Partner Nate Lacktman was quoted in a Modern Healthcare article, “Tapping Telehealth for Complex Cases,” which covers how physicians are beginning to utilize telehealth capabilities to offer remote assistance for high-acuity patients. The article discusses telehealth’s positive effects on low-acuity patients thanks to direct-to-consumer telehealth platforms and explores the potential for the service to move into the high-acuity space.
Lacktman was quoted saying that direct-to-consumer companies “have done a good job of expanding access to low-acuity care. But health systems are well-positioned to use technology to care for the ‘sickest of the sick’ who account for the greatest share of healthcare spending.” He pointed out that the health system to “crack that nut … will be a game-changer.”
Lacktman was quoted saying that direct-to-consumer companies “have done a good job of expanding access to low-acuity care. But health systems are well-positioned to use technology to care for the ‘sickest of the sick’ who account for the greatest share of healthcare spending.” He pointed out that the health system to “crack that nut … will be a game-changer.”
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."